

Appendix 1: Estimated percentage of true-positive, true-negative, false-positive and false-negative results expected with each testing strategy used to determine HER2 status

Testing strategy†	Type of result; % of patients, median (95% credible interval)*				% of patients who would receive trastuzumab (95% credible interval)*
	True positive	False positive	True negative	False negative	
Strategy 1 (base strategy)	19 (14-25)	1 (0.6-2)	78 (72-83)	2 (1-3)	20 (15-27)
Strategy 2	19 (14-25)	9 (4-17)	69 (62-76)	2 (1-3)	28 (22-36)
Strategy 3	15 (10-21)	1 (0.6-2)	78 (72-83)	6 (3-11)	16 (11-23)
Strategy 4	21 (16-26)	1 (0.6-2)	78 (72-83)	0.6 (0-1)	21 (16-28)
Strategy 5 (selected strategy‡)	19 (14-25)	0	79 (73-84)	2 (1-3)	19 (14-25)
Strategy 6	21 (16-26)	0	79 (73-84)	0.6 (0-1)	20 (15-26)
Strategy 7	21 (16-27)	0	79 (73-84)	0	21 (16-27)

*Percentages in each row may not add to 100 owing to rounding.

†See Table 1 for descriptions of testing strategies.

‡Selected as having the lowest incremental cost-effectiveness ratio.